Yong W. Yi

Cheonan, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

From Orange to Oncology: Anti-Inflammatory and Anti-Cancer Mechanisms of Sinensetin.

From Orange to Oncology: Anti-Inflammatory and Anti-Cancer Mechanisms of Sinensetin.

Journal: Cells

Published: November 26, 2025

A review on ribosomal protein S3 (RPS3): Roles in cancer and its resistance to drugs.

A review on ribosomal protein S3 (RPS3): Roles in cancer and its resistance to drugs.

Journal: International journal of biological macromolecules

Published: February 19, 2025

JAK2 Inhibition Augments the Anti-Proliferation Effects by AKT and MEK Inhibition in Triple-Negative Breast Cancer Cells.

JAK2 Inhibition Augments the Anti-Proliferation Effects by AKT and MEK Inhibition in Triple-Negative Breast Cancer Cells.

Journal: International journal of molecular sciences

Published: February 05, 2025

Structure-activity relationship analysis of mono-methylated quercetins by comprehensive MS/MS analysis and anti-proliferative efficacy in human colorectal cancer cells.

Structure-activity relationship analysis of mono-methylated quercetins by comprehensive MS/MS analysis and anti-proliferative efficacy in human colorectal cancer cells.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 19, 2024

Identification of sinensetin as a selective inhibitor for mitogen-activated protein kinase kinase 6 and an anticancer agent for non-small cell lung cancer.

Identification of sinensetin as a selective inhibitor for mitogen-activated protein kinase kinase 6 and an anticancer agent for non-small cell lung cancer.

Journal: American journal of cancer research

Published: November 06, 2024

Therapeutic implication of oxidative stress-induced growth inhibitor 1 (OSGIN1) in cancer.

Therapeutic implication of oxidative stress-induced growth inhibitor 1 (OSGIN1) in cancer.

Journal: Oncogene

Published: August 28, 2024

Beta-Transducin Repeats-Containing Proteins as an Anticancer Target.

Beta-Transducin Repeats-Containing Proteins as an Anticancer Target.

Journal: Cancers

Published: July 31, 2023

Extracellular Vesicles as a New Therapeutic Entity.

Extracellular Vesicles as a New Therapeutic Entity.

Journal: Life (Basel, Switzerland)

Published: May 18, 2023

OSGIN1 is a novel TUBB3 regulator that promotes tumor progression and gefitinib resistance in non-small cell lung cancer.

OSGIN1 is a novel TUBB3 regulator that promotes tumor progression and gefitinib resistance in non-small cell lung cancer.

Journal: Cellular and molecular life sciences : CMLS

Published: April 17, 2023

Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells.

Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells.

Journal: International journal of molecular sciences

Published: January 10, 2023

TGFβ4 alleviates the phenotype of Charcot-Marie-Tooth disease type 1A.

TGFβ4 alleviates the phenotype of Charcot-Marie-Tooth disease type 1A.

Journal: Brain : a journal of neurology

Published: October 08, 2022

Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells.

Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells.

Journal: Cancers

Published: September 29, 2022

Showing 1-12 of 42

Last Updated: 09/26/2026